Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sample Size Calculation01:19

Sample Size Calculation

3.3K
Knowledge of the sample size is the first requirement to conduct random sampling or an experiment. The sample size is the total number of units, observations, or groups (in some cases) used to get the data to estimate a population parameter. As the name suggests, the sample size is that of the sample drawn from the population and differs from the population size.
The sample size for the given experiment or sampling effort is fundamental to any study design. Sample size decides the number of...
3.3K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

256
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
256
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

371
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
371
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

981
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
981

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple Testing of Mix-and-Match Feature Sets in Multi-Omics.

Statistics in medicine·2026
Same author

Temporal Dynamics of Neural Response to Drug Cues in abstinent Methamphetamine Users.

Basic and clinical neuroscience·2024
Same author

A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2023
Same author

The individual-level surrogate threshold effect in a causal-inference setting with normally distributed endpoints.

Pharmaceutical statistics·2021
Same author

Pathway testing for longitudinal metabolomics.

Statistics in medicine·2021
Same author

Inflated false discovery rate due to volcano plots: problem and solutions.

Briefings in bioinformatics·2021
Same journal

Impact of Information Leakage in Platform Trials With Survival Endpoints on Type I Error Control.

Pharmaceutical statistics·2026
Same journal

Harmonic Fowlkes-Mallows Index for Medical Diagnostics Tests and Optimal Cut-Off Point Selection of Binary Diseases.

Pharmaceutical statistics·2026
Same journal

Early Phase Dose-Finding Designs for CAR-T Cell Therapies.

Pharmaceutical statistics·2026
Same journal

Optimizing Randomization Ratios in Clinical Trials With Survival Endpoints.

Pharmaceutical statistics·2026
Same journal

CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized Trials.

Pharmaceutical statistics·2026
Same journal

Will the Pharmaceutical Industry Need Statisticians in an AI World?

Pharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.6K

On sample size calculation in drug interaction trials.

Paul Meyvisch1, Mitra Ebrahimpoor2

  • 1I-BioStat, Universiteit Hasselt, Diepenbeek, Belgium.

Pharmaceutical Statistics
|February 15, 2024
PubMed
Summary
This summary is machine-generated.

Calculating sample sizes for drug-drug interaction trials can be simplified. A new precision-based method requires fewer participants and accounts for potential interactions, improving drug development efficiency.

Keywords:
drug interactionprecision

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

Related Experiment Videos

Last Updated: Jul 3, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.6K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.7K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

Area of Science:

  • Pharmacokinetics and Drug Development
  • Clinical Trial Design
  • Statistical Methodology in Pharmacology

Background:

  • Drug-drug interaction (DDI) trials are crucial for assessing concomitant medication risks and benefits.
  • Traditional sample size calculations for DDIs rely on difficult-to-define no-effect boundaries, often leading to overly conservative estimates and large sample sizes.
  • Existing methods are insufficient when prior evidence suggests a mild or moderate interaction may exist, necessitating effect boundaries.

Purpose of the Study:

  • To introduce a novel precision-based sample size calculation method for DDI trials.
  • To provide a more efficient and adaptable approach compared to traditional no-effect boundary methods.
  • To account for pharmacokinetic variability and anticipated interaction boundaries.

Main Methods:

  • Developed a precision-based sample size calculation framework.
  • Incorporated stochastic pharmacokinetic parameters into the calculation.
  • Considered the width of potential no-effect or effect boundaries.

Main Results:

  • The proposed precision-based method requires a considerably smaller sample size.
  • The methodology demonstrates favorable operating characteristics.
  • A case study involving statins illustrated the practical application and benefits.

Conclusions:

  • Precision-based sample size calculation offers a more efficient and practical approach for DDI trials.
  • This method is advantageous when dealing with pharmacokinetic variability and known or anticipated interactions.
  • The approach can streamline drug development by optimizing sample size requirements.